培美曲塞联合顺铂治疗晚期肺腺癌的临床分析

目的评价培美曲塞联合顺铂治疗晚期肺腺癌的疗效和毒副反应。方法 35例经病理或细胞学确诊的晚期肺腺癌初治患者,采用培美曲塞500mg/m2,第1天给药,并口服地塞米松、叶酸和肌内注射维生素B12预处理;顺铂75mg/m2,静滴,分2～4d给药,均予以保肝、护胃、止吐药物。治疗21d为1个周期,2个周期后评价疗效、毒副反应。结果 35例患者中,客观有效率为29%,疾病控制率为69%,PFS8个月(2～12个月),中位总生存期9个月(3～19个月)。毒副反应主要是骨髓抑制、胃肠道反应,均未达到Ⅲ～Ⅳ度。结论培美曲塞联合顺铂一线治疗晚期肺腺癌疗效较好,毒性反应轻,值得临床推广应用。

Clinical observation of pemetrexed combined with cisplatin in the first-line treating advanced lung adenocarcinoma

Objective To observe the clinical efficacy and adverse effect of pemetrexed combined with cisplatin in the first-line treating advanced lung adenocarcinoma. Methods A total of 35 patients with advanced lung adenocarcinoma cell of histology diagnosed by pathology or cytology were enrolled into the study.The patients were treated with pemetrexed and cisplatin.Each patient were received 2 cycles chemotherapy at least.The short term effect,side effects were evaluated after chemotherapy. Results RR was 29%(10/35),DCR were 69%,median PFS 8 months and median OS 9 months.The main side effect were bone marrow suppression,but that were tolerable. Conclusion Pemetrexed combined with cisplatin were effective,safe and well tolerable in the first-line treatment of advanced lung adenocarcinoma.